 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Triangle Pharmaceuticals, Inc.
 |
Triangle Pharmaceuticals, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Triangle Pharmaceuticals reports Q2 loss, layoffs Aug 06 2001 04:05 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Triangle Pharmaceuticals is developing a bevy of new drug candidates, primarily antiviral therapies. Triangle's emphasis is on treating HIV, AIDS, and the hepatitis B virus using combinations of drugs, a method that shows promise in treating HIV. The development-stage firm focuses on drug development rather than the time-consuming, expensive process of drug discovery. The company has license agreements with Emory University and the University of Georgia for various drug candidates, as well as with Abbott Laboratories (which owns nearly one-fifth of the company) to produce antiviral compounds.
COMPETITION |
 |
Agouron Pharmaceuticals, Inc. (dossier)
GlaxoSmithKline plc (GSK)
Vertex Pharmaceuticals Incorporated (VRTX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 7.30
1-Yr. Sales Growth: 7,200.0%
Employees: 170
Revenue per employee: $42,941.18
KEY PEOPLE |
 |
David W. Barry
CEO
Robert F. Amundsen
CFO
CONTACT INFO |
 |
4 University Place, 4611 University Dr.
Durham, NC 27707
US
Phone: 919-493-5980
Fax: 919-493-5925
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |